BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 14747567)

  • 1. Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitro.
    McAuliffe JM; Surman SR; Newman JT; Riggs JM; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2029-36. PubMed ID: 14747567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
    Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
    Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
    J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2006 Mar; 24(14):2674-84. PubMed ID: 16364511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.
    Bartlett EJ; Amaro-Carambot E; Surman SR; Newman JT; Collins PL; Murphy BR; Skiadopoulos MH
    Vaccine; 2005 Sep; 23(38):4631-46. PubMed ID: 15951066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Surman SR; Durbin AP; Collins PL; Murphy BR
    Virology; 2000 Jun; 272(1):225-34. PubMed ID: 10873765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live influenza A virus vaccine.
    Subbarao EK; Park EJ; Lawson CM; Chen AY; Murphy BR
    J Virol; 1995 Oct; 69(10):5969-77. PubMed ID: 7666501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.
    Skiadopoulos MH; Surman S; Tatem JM; Paschalis M; Wu SL; Udem SA; Durbin AP; Collins PL; Murphy BR
    J Virol; 1999 Feb; 73(2):1374-81. PubMed ID: 9882342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Codon stabilization analysis of the "248" temperature sensitive mutation for increased phenotypic stability of respiratory syncytial virus vaccine candidates.
    Luongo C; Yang L; Winter CC; Spann KM; Murphy BR; Collins PL; Buchholz UJ
    Vaccine; 2009 Sep; 27(41):5667-76. PubMed ID: 19646406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
    Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
    Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes.
    Whitehead SS; Firestone CY; Collins PL; Murphy BR
    Virology; 1998 Aug; 247(2):232-9. PubMed ID: 9705916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
    Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
    Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human parainfluenza virus 3 vaccine candidates attenuated by codon-pair deoptimization are immunogenic and protective in hamsters.
    Afroz S; Saul S; Dai J; Surman S; Liu X; Park HS; Le Nouën C; Lingemann M; Dahal B; Coleman JR; Mueller S; Collins PL; Buchholz UJ; Munir S
    Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2316376121. PubMed ID: 38861603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.
    Bartlett EJ; Cruz AM; Boonyaratanakornkit J; Esker J; Castaño A; Skiadopoulos MH; Collins PL; Murphy BR; Schmidt AC
    Vaccine; 2010 Jan; 28(3):767-79. PubMed ID: 19857454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.
    Luongo C; Winter CC; Collins PL; Buchholz UJ
    J Virol; 2012 Oct; 86(19):10792-804. PubMed ID: 22837193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Codon Deletions in the Influenza A Virus PA Gene Generate Temperature-Sensitive Viruses.
    Meyer L; Sausset A; Sedano L; Da Costa B; Le Goffic R; Delmas B
    J Virol; 2016 Jan; 90(7):3684-93. PubMed ID: 26792748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.
    Bartlett EJ; Hennessey M; Skiadopoulos MH; Schmidt AC; Collins PL; Murphy BR; Pickles RJ
    J Virol; 2008 Aug; 82(16):8059-70. PubMed ID: 18524813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.